The Emergence of Thalidomide in Treating Advanced Renal Cell Carcinoma

Laura S. Wood

Cherie Perez

Dana Monroe

ONF 2003, 30(3), 501-511. DOI: 10.1188/03.ONF.501-511

Purpose/Objectives: To review standard and investigational treatments in advanced renal cell carcinoma, with a focus on thalidomide.

Data Sources: Published articles, conference proceedings, treatment guidelines, and textbooks.

Data Synthesis: The prognosis for advanced renal cell carcinoma when treated with standard regimens is poor; therefore, new treatments are needed.

Conclusions: Treatment with thalidomide, alone and in combination with other therapies, may improve survival for patients with advanced renal cell carcinoma.

Implications for Nursing: Proactive management of adverse effects associated with thalidomide, alone and in combination, may increase patient tolerance and compliance.

Jump to a section

    References

    Amato, R. (2000). Chemotherapy for renal cell carcinoma. Seminars in Oncology, 27, 177-186.

    Amato, R.J., Breheny, S., & Tracy, E. (2002). Phase I/II study of thalidomide + interleukin II (IL-2) for patients with metastatic renal cell carcinoma [Abstract 759]. Proceedings of the American Society of Clinical Oncology, 21, 190a.

    Bukowski, R.M. (2001). Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urologic Oncology, 19, 148-154.

    Bukowski, R.M., & Novik, A.C. (1997). Renal-cell carcinoma. New England Journal of Medicine, 335, 865-875.

    Celgene Corporation. (2003). Thalomid® [Package insert]. Warren, NJ: Author.

    Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., et al. (2000). Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New England Journal of Medicine, 343, 750-758.

    Ching, L.M., Xu, Z.F., Gummer, B.H., Palmer, B.D., Joseph, W.R., & Baguley, B.C. (1995). Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxantheone-4-acetic acid. British Journal of Cancer, 72, 339-343.

    D'Amato, R.J., Loughnan, M.S., Flynn, E., & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.

    Dhote, R., Pellicer-Coeuret, M., Thiounn, N., Debre, B., & Vidal-Trecan, G. (2000). Risk factors for adult renal cell carcinoma: A systematic review and implications for prevention. British Journal of Urology International, 86(1), 20-27.

    Early, L.M., & Poquette, R.M. (2000). Bladder and kidney cancer. In C.H. Yarbro, M. Goodman, M.H. Frogge, & S.L. Groenwald, (Eds.) Cancer nursing: Principles and practice (5th ed., pp. 973-993). Boston: Jones and Bartlett.

    Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M.M., Pyle, L., et al. (2000). Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. British Journal of Cancer, 82, 812-817.

    Eisen, T.G. (2000). Thalidomide in solid tumors: The London experience. Oncology (Huntington), 14(12 Suppl. 13), 17-20.

    Escudier, B., Lassau, N., Couanet, D., Angevin, E., Leborgne, S., Garofano, A., et al. (2001). Phase II trial of thalidomide in renal-cell carcinoma [Abstract 718]. Proceedings of the American Society of Clinical Oncology, 20, 180a.

    Figlin, R.A. (2000). Renal cell carcinoma: Current status and future plans. Cancer Journal From Scientific American, 1(Suppl. 6), S52-S54.

    Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., Bearman, S.I., Roy, V., McGrath, P.C., et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine, 345, 1655-1659.

    Fleming, I.D., Cooper, J.S., Henson, D.E., Hutter, R.V.P., Kennedy, B.J., Murphy, G.P., et al. (1998). AJCC cancer staging manual (5th ed., pp. 215-218). Philadelphia: Lippincott Williams and Wilkins.

    Folkman, J. (1995). Clinical applications of research on angiogenesis. New England Journal of Medicine, 333, 1757-1763.

    Fyfe, G., Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.M., & Louie, A.C. (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of Clinical Oncology, 13, 688-696.

    Godley, P.A., & Taylor, M. (2001). Renal cell carcinoma. Current Opinion in Oncology, 13, 199-203.

    Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. (2003). Cancer statistics, 2003. CA: A Cancer Journal for Clinicians, 53, 5-26.

    Kriegmair, M., Oberneder, R., & Hofstetter, A. (1995). Interferon alpha and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology, 45, 758-762.

    Law, T.M., Motzer, R.J., Mazumdar, M., Sell, K.W., Walther, P.J., O'Connell, M., et al. (1995). Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76, 824-832.

    Lenz, W. (1966). Malformations caused by drugs in pregnancy. American Journal of Diseases of Children, 2, 99-106.

    Lenz, W. (1968). The susceptible period for thalidomide malformations in man and monkey. German Medical Monthly, 4, 197-198.

    Li, Z., Amato, R., Papandreou, C., Pagliaro, L., Kim, J., Millikan, R., et al. (2001). Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCCD) progressing after interleukin-2 (IL-2)-based therapy (Rx) [Abstract 717]. Proceedings of the American Society of Clinical Oncology, 20, 180a.

    Linehan, W.M., Zbar, B., Bates, S.E., Zelefsky, M.J., & Yang, J.C. (2001). Cancer of the kidney and ureter. In V.T. DeVita, S. Hellman, & S.A. Rosenberg, (Eds.) Cancer: Principles and practice of oncology (6th ed., pp. 1362-1396). Philadelphia: Lippincott Williams and Wilkins.

    Lopez-Hanninen, E., Kirchner, H., & Atpodien, J. (1996). Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. Journal of Urology, 155, 19-25.

    Mancilla-Jimenez, R., Stanley, R.J., & Blath, R.A. (1976). Papillary renal cell carcinoma: A clinical, radiologic, and pathologic study of 34 cases. Cancer, 38, 2469-2480.

    Medical Research Council Renal Cancer Collaborators. (1999). Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet, 353, 14-17.

    Middleton, R.G. (1967). Surgery for metastatic renal cell carcinoma. Journal of Urology, 97, 973-977.

    Minor, D., & Elias, L. (2000). Thalidomide treatment of metastatic renal cell carcinoma [Abstract 1384]. Proceedings of the American Society of Clinical Oncology, 19, 352a.

    Motzer, R.J. (1997). Chemotherapy for renal cell carcinoma. In D. Raghavan, H.I. Scher, S.A. Leibel, & P.H. Lange, (Eds.) Principles and practice of genitourinary oncology (pp. 885-896). Philadelphia: Lippincott-Raven.

    Motzer, R.J., Bahnson, R.R., Carducci, M.A., Fishman, M., Hancock, S.L., Hauke, R.J., et al. (2002). NCCN practice guidelines for kidney cancer. In The complete library of NCCN practice guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network.

    Motzer, R.J., Bander, N.H., & Nanus, D.M. (1996). Renal-cell carcinoma. New England Journal of Medicine, 335, 865-875.

    Motzer, R.J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R., et al. (2002). Phase II trial of thalidomide for patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 20, 302-306.

    Motzer, R.J., Mazumdar, M., Bacik, J., Russo, P., Berg, W.J., & Metz, E.M. (2000). Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 18, 1928-1935.

    Motzer, R.J., Murphy, M., Mazumdar, M., Loehrer, P., Wilding, G., Schwartz, T., et al. (1999). Randomized phase III trial of interferon alfa-2a (IFN) versus IFN plus 13-cis-retinoic acid (CRA) in patients with advanced renal cell carcinoma (RCC) [Abstract 1271]. Proceedings of the American Society of Clinical Oncology, 18, 330a.

    Nanus, D.M. (2000). New treatment approaches for metastatic renal cell carcinoma. Current Oncology Reports, 2, 417-422.

    Newhouse, J.H. (1993). The radiologic evaluation of the patient with renal cell cancer. Urologic Clinics of North America, 20, 231-246.

    Novik, Y., Kutcher, J.P., Larkin, M., & Wiernik, P.H. (2001). Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC): A single institution experience [Abstract 1057]. Proceedings of the American Society of Clinical Oncology, 20, 265a.

    Olencki, T., Dreicer, R., Elson, P., Wood, L., & Bukowski, R.M. (2002). Phase I trial of thalidomide and interleukin-2 (IL-2) in patients (pts) with metastatic renal cell carcinoma (RCC) [Abstract 2430]. Proceedings of the American Society of Clinical Oncology, 21, 154b.

    Pantuck, A.J., Zisman, A., & Belldegrun, A. (2001). Biology of renal cell carcinoma: Changing concepts in classification and staging. Seminars in Urologic Oncology, 19, 72-79.

    Pyrhonen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., et al. (1999). Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. Journal of Clinical Oncology, 17, 2859-2867.

    Richardson, P., Hideshima, T., & Anderson, K. (2002). Thalidomide: Emerging role in cancer medicine. Annual Review of Medicine, 53, 629-657.

    Rini, B.I., Vogelzang, N.J., Dumas, M.C., Wade, J.L., Taber, D.A., & Stadler, W.M. (2000). Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. Journal of Clinical Oncology, 18, 2419-2426.

    Robson, C.J., Churchill, B.M., & Anderson, W. (1969). The results of radical nephrectomy for renal cell carcinoma. Journal of Urology, 101, 297-301.

    Russo, P. (2000). Renal cell carcinoma: Presentation, staging, and surgical treatment. Seminars in Oncology, 27, 160-176.

    Skinner, D.G., Colvin, R.B., Vermillion, C.D., Pfister, R.C., & Leadbetter, W.F. (1971). Diagnosis and management of renal cell carcinoma: A clinical and pathologic study of 309 cases. Cancer, 28, 1165-1177.

    Srinivas, S. (2001). A randomized trial of two dosing schedules of oral thalidomide in metastatic renal cell carcinoma [Abstract 2386]. Proceedings of the American Society of Clinical Oncology, 20, 159a.

    Stebbing, J., Benson, C., Eisen, T., Pyle, L., Smalley, K., Bridle, H., et al. (2001). The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer, 85, 953-958.

    Studer, U.E., Scherz, S., Scheidegger, J., Kraft, R., Sonntag, R., Ackermann, D., et al. (1990). Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. Journal of Urology, 144, 243-245.

    Tammela, T.L., Leinonen, A.S., & Kontturi, M.J. (1991). Comparison of excretory urography, angiography, ultrasound, and computed tomography for T category staging of renal cell carcinoma. Scandinavian Journal of Urology and Nephrology, 25, 283-286.

    Vogelzang, N.J., Lipton, A., & Figlin, R.A. (1993). Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multi-center trial. Journal of Clinical Oncology, 11, 1809-1816.

    Vogelzang, N.J., & Stadler, W.M. (1998). Kidney cancer. Lancet, 352, 1691-1696.

    Wirth, M.P. (1993). Immunotherapy for metastatic renal cell carcinoma. Urologic Clinics of North America, 20, 283-295.

    Wolchok, J.D., & Motzer, R.J. (2000). Management of renal cell carcinoma. Oncology (Huntington), 14(1), 29-36.

    Yagoda, A., Abi-Rached, B., & Petrylak, D. (1995). Chemotherapy for advanced renal-cell carcinoma: 1983-1995. Seminars in Oncology, 22, 42-60.

    Yagoda, A., Petrylak, D., & Thompson, S. (1993). Cytotoxic chemotherapy for advanced renal cell carcinoma. Urologic Clinics of North America, 20, 303-321.

    Yang, J.C., & Rosenberg, S.A. (1997). An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer Journal From Scientific American, 3(Suppl. 1), S79-S84.

    Yang, J.C., Topalian, S.T., Parkinson, D., Schwartzentruber, D.J., Weber, J.S., Ettinghausen, S.E., et al. (1994). Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. Journal of Clinical Oncology, 12, 1572-1576.

    Zambrano, N.R., Lubensky, I.A., Merino, M.J., Linehan, W.M., & Walther, M.M. (1999). Histopathology and molecular genetics of renal tumors toward unification of a classification system. Journal of Urology, 162, 1246-1258.

    Zeldis, J.B., Williams, B.A., Thomas, S.D., & Elsayed, M.E. (1999). S.T.E.P.S: A comprehensive program for controlling and monitoring access to thalidomide. Clinical Therapeutics, 21, 319-330.